Education Pfizer’s HYMPAVZI Cuts Bleeding by 93% in Hemophilia Patients Pfizer Inc. announced significant findings from its Phase 3 BASIS study, revealing that HYMPAVZI® (marstacimab) dramatically reduces bleeding episodes in adults and adolescents with... Editorial23 hours ago